Wednesday, July 26, 2023
Beckman Coulter Diagnostics, a prominent player in the field of clinical diagnostics, has recently received FDA clearance for its latest offering - the DxC 500 AU Chemistry Analyzer. This cutting-edge automated chemistry analyzer expands the company's range of clinical chemistry solutions and demonstrates its ongoing commitment to innovation within the in vitro diagnostic industry.
The DxC 500 AU Chemistry Analyzer is specially designed for small-to-medium-sized laboratories, aiming to streamline workflows and provide valuable support for critical clinical decisions. Utilizing standardized assays and reagents shared across Beckman Coulter's AU clinical chemistry analyzers ensures timely and precise patient results, benefiting both independent laboratories and integrated networks by delivering consistent outcomes for clinical decision-making and improved patient care.
The use of the same reagents across various chemistry platforms not only enables comparable patient results but also has a positive impact on inventory management and cost-effectiveness within healthcare systems. The Beckman Coulter DxC 500 AU Clinical Chemistry Analyzer has undergone rigorous assessment using Six Sigma metrics, surpassing the demanding requirements of CLIA 2024 performance specifications.
Given that diagnostic testing heavily influences medical decisions (70%), there is an increasing demand for accuracy and reliability of results. The DxC 500 AU Chemistry Analyzer's extensive menu of over 120 assays has been independently verified for its high-quality performance, instilling confidence in the integrity of the test results. The DxC 500 AU Chemistry Analyzer is intended for in vitro diagnostic use only.
Source: prnewswire.com
